NASDAQ:RDHLREDHILL BIOPHAR/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding REDHILL BIOPHAR/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.09 -0.03 (-0.42 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$6.93Now: $7.09▼$7.2050-Day Range$6.05MA: $7.04▼$8.6052-Week Range$3.26Now: $7.09▼$9.12Volume182,938 shsAverage Volume316,700 shsMarket Capitalization$250.06 millionP/E RatioN/ADividend YieldN/ABeta1.7 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors. It is also developing YELIVA that is in Phase IIa clinical trial for the treatment of advanced unresectable cholangiocarcinoma; is in Phase Ib/II clinical trial for refractory or relapsed multiple myeloma; and is in Phase II clinical trial for the treatment of advanced hepatocellular carcinoma. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.Read More Beat the Market (BTM) Rank™ 3.7 Analyst's Opinion Consensus RatingREDHILL BIOPHAR/S has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.25, REDHILL BIOPHAR/S has a potential upside of 143.3% from its current price of $7.09.Amount of Analyst CoverageREDHILL BIOPHAR/S has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesREDHILL BIOPHAR/S has received 395 “outperform” votes. (Add your “outperform” vote.)Underperform VotesREDHILL BIOPHAR/S has received 274 “underperform” votes. (Add your “underperform” vote.)Community SentimentREDHILL BIOPHAR/S has received 59.04% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about REDHILL BIOPHAR/S and other stocks. Vote “Outperform” if you believe RDHL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RDHL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldREDHILL BIOPHAR/S does not currently pay a dividend.Dividend GrowthREDHILL BIOPHAR/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, REDHILL BIOPHAR/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 17.62% of the stock of REDHILL BIOPHAR/S is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for REDHILL BIOPHAR/S are expected to grow in the coming year, from ($0.68) to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of REDHILL BIOPHAR/S is -4.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of REDHILL BIOPHAR/S is -4.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioREDHILL BIOPHAR/S has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.7Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDHL Previous Symbol CUSIPN/A CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Debt Debt-to-Equity Ratio1.88 Current Ratio5.83 Quick Ratio5.67Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.29 million Price / Sales39.76 Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / Book2.59Profitability EPS (Most Recent Fiscal Year)($1.40) Net Income$-42,300,000.00 Net Margins-883.97% Return on Equity-125.23% Return on Assets-64.50%Miscellaneous Employees75 Outstanding Shares35,270,000Market Cap$250.06 million Next Earnings Date7/28/2020 (Estimated) OptionableOptionable NASDAQ:RDHL Rates by TradingView Receive RDHL News and Ratings via Email Sign-up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. REDHILL BIOPHAR/S (NASDAQ:RDHL) Frequently Asked Questions How has REDHILL BIOPHAR/S's stock been impacted by COVID-19 (Coronavirus)? REDHILL BIOPHAR/S's stock was trading at $3.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RDHL shares have increased by 77.7% and is now trading at $7.09. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of REDHILL BIOPHAR/S? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REDHILL BIOPHAR/S in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for REDHILL BIOPHAR/S. When is REDHILL BIOPHAR/S's next earnings date? REDHILL BIOPHAR/S is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for REDHILL BIOPHAR/S. How were REDHILL BIOPHAR/S's earnings last quarter? REDHILL BIOPHAR/S (NASDAQ:RDHL) announced its quarterly earnings results on Wednesday, May, 27th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.12. The biotechnology company earned $1.06 million during the quarter, compared to the consensus estimate of $3.79 million. REDHILL BIOPHAR/S had a negative net margin of 883.97% and a negative return on equity of 125.23%. View REDHILL BIOPHAR/S's earnings history. What price target have analysts set for RDHL? 3 brokers have issued 12-month target prices for REDHILL BIOPHAR/S's stock. Their forecasts range from $14.00 to $23.00. On average, they anticipate REDHILL BIOPHAR/S's stock price to reach $17.25 in the next twelve months. This suggests a possible upside of 143.3% from the stock's current price. View analysts' price targets for REDHILL BIOPHAR/S. Has REDHILL BIOPHAR/S been receiving favorable news coverage? Media coverage about RDHL stock has trended very positive recently, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. REDHILL BIOPHAR/S earned a media sentiment score of 3.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutREDHILL BIOPHAR/S. Who are some of REDHILL BIOPHAR/S's key competitors? Some companies that are related to REDHILL BIOPHAR/S include Applied Therapeutics (APLT), MacroGenics (MGNX), BioXcel Therapeutics (BTAI), Stoke Therapeutics (STOK), Athenex (ATNX), Endo International (ENDP), Amphastar Pharmaceuticals (AMPH), NextCure (NXTC), Rhythm Pharmaceuticals (RYTM), Passage Bio (ORIC), ImmunoGen (IMGN), Omeros (OMER), Gossamer Bio (GOSS), Cue Biopharma (CUE) and Kura Oncology (KURA). View all competitors. What other stocks do shareholders of REDHILL BIOPHAR/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other REDHILL BIOPHAR/S investors own include Agenus (AGEN), Aralez Pharmaceuticals (ARLZ), Sorrento Therapeutics (SRNE), Verastem (VSTM), Amarin (AMRN), Sangamo Therapeutics (SGMO), Progenics Pharmaceuticals (PGNX), Synergy Pharmaceuticals (SGYP), Protalix Biotherapeutics (PLX) and Exelixis (EXEL). Who are REDHILL BIOPHAR/S's key executives? REDHILL BIOPHAR/S's management team includes the following people: Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 53)Mr. Micha Ben-Chorin, Chief Financial Officer (Age 50)Mr. Gilead Raday, Chief Operating Officer (Age 44)Mr. Adi Frish, Sr. VP of Bus. Devel. & Licensing (Age 49)Mr. Guy Goldberg, Chief Bus. Officer (Age 43) What is REDHILL BIOPHAR/S's stock symbol? REDHILL BIOPHAR/S trades on the NASDAQ under the ticker symbol "RDHL." Who are REDHILL BIOPHAR/S's major shareholders? REDHILL BIOPHAR/S's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Ibex Investors LLC (5.25%), Disciplined Growth Investors Inc. MN (4.83%), Creative Planning (1.18%), Gagnon Securities LLC (0.28%), State Street Corp (0.27%) and Sowell Financial Services LLC (0.25%). Which major investors are selling REDHILL BIOPHAR/S stock? RDHL stock was sold by a variety of institutional investors in the last quarter, including Disciplined Growth Investors Inc. MN, Gagnon Securities LLC, and CLARET ASSET MANAGEMENT Corp. Which major investors are buying REDHILL BIOPHAR/S stock? RDHL stock was acquired by a variety of institutional investors in the last quarter, including Ibex Investors LLC, Phoenix Holdings Ltd., Sowell Financial Services LLC, Creative Planning, Jane Street Group LLC, Sanders Morris Harris LLC, Sanders Morris Harris LLC, and State Street Corp. How do I buy shares of REDHILL BIOPHAR/S? Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is REDHILL BIOPHAR/S's stock price today? One share of RDHL stock can currently be purchased for approximately $7.09. How big of a company is REDHILL BIOPHAR/S? REDHILL BIOPHAR/S has a market capitalization of $250.06 million and generates $6.29 million in revenue each year. The biotechnology company earns $-42,300,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. REDHILL BIOPHAR/S employs 75 workers across the globe. What is REDHILL BIOPHAR/S's official website? The official website for REDHILL BIOPHAR/S is www.redhillbio.com. How can I contact REDHILL BIOPHAR/S? REDHILL BIOPHAR/S's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
